Article Versions Notes

Souto EB, Silva GF, Dias-Ferreira J, Zielinska A, Ventura F, Durazzo A, Lucarini M, Novellino E, Santini A. Nanopharmaceutics: Part I—Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU. Pharmaceutics. 2020; 12(2):146. https://doi.org/10.3390/pharmaceutics12020146

Souto, Eliana B., Gabriela F. Silva, João Dias-Ferreira, Aleksandra Zielinska, Fátima Ventura, Alessandra Durazzo, Massimo Lucarini, Ettore Novellino, and Antonello Santini. 2020. "Nanopharmaceutics: Part I—Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU" Pharmaceutics 12, no. 2: 146. https://doi.org/10.3390/pharmaceutics12020146

Souto, E. B., Silva, G. F., Dias-Ferreira, J., Zielinska, A., Ventura, F., Durazzo, A., Lucarini, M., Novellino, E., & Santini, A. (2020). Nanopharmaceutics: Part I—Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU. Pharmaceutics, 12(2), 146. https://doi.org/10.3390/pharmaceutics12020146